当前位置: X-MOL 学术Cell. Mol. Biol. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Silencing of Synuclein-γ inhibits human cervical cancer through the AKT signaling pathway.
Cellular & Molecular Biology Letters ( IF 8.3 ) Pub Date : 2019-07-10 , DOI: 10.1186/s11658-019-0172-y
Chunnian Zhang 1 , Liqin Gu 1 , Xiafang Li 1 , Jianzhong Wang 1
Affiliation  

BACKGROUND Synuclein-γ has been demonstrated to be highly expressed in various human cancers including cervical cancer, and has been shown to play a critical role in tumor aggressiveness. We aimed to investigate the role of Synuclein-γ in human cervical cancer in vitro and in vivo. METHOD Reverse transcription-quantitative polymerase chain reaction assay and Western blot assay were used to detect the mRNA and protein expression, respectively. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and colony formation assay were performed to measure the viabilities of cancer cells. Flow cytometry assay was used to detect the cell cycle and apoptosis. Moreover, an animal experiment was performed to evaluate the biological behavior of Synuclein-γ in vivo. RESULTS In the current study, we found that Synuclein-γ was obviously over-expressed in cervical cancer tissues compared to the adjacent non-cancer tissues. Cervical cancer cells transfected with Synuclein-γ siRNA demonstrated significant inhibition of cancer proliferation (P < 0.01), cell cycle arrest at G0/G1 phase, and cell apoptosis (P < 0.05). Moreover, down-regulation of Synuclein-γ significantly inhibited cervical cancer growth in vivo. In addition, protein levels of AKT, c-Myc and Cyclin D1 were much lower in the Synuclein-γ siRNA-treated groups than that in the control group. CONCLUSIONS Synuclein-γ inhibition reduced cervical cancer tumor growth through the AKT pathway. This effect represented a therapeutic opportunity and provided a novel target for cervical cancer treatment.

中文翻译:

Synuclein-γ 的沉默通过 AKT 信号通路抑制人宫颈癌。

背景技术突触核蛋白-γ已被证明在包括宫颈癌在内的多种人类癌症中高度表达,并且已被证明在肿瘤侵袭性中起关键作用。我们的目的是在体外和体内研究 Synuclein-γ 在人宫颈癌中的作用。方法采用逆转录-定量聚合酶链反应法和Western印迹法分别检测mRNA和蛋白的表达。进行3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑测定和集落形成测定以测量癌细胞的活力。流式细胞仪检测细胞周期和细胞凋亡。此外,还进行了动物实验以评估 Synuclein-γ 在体内的生物学行为。结果 在目前的研究中,我们发现与邻近的非癌组织相比,Synuclein-γ 在宫颈癌组织中明显过表达。转染 Synuclein-γ siRNA 的宫颈癌细胞表现出显着抑制癌细胞增殖(P < 0.01)、细胞周期停滞在 G0/G1 期和细胞凋亡(P < 0.05)。此外,Synuclein-γ 的下调显着抑制了体内宫颈癌的生长。此外,在 Synuclein-γ siRNA 处理组中,AKT、c-Myc 和 Cyclin D1 的蛋白质水平远低于对照组。结论 Synuclein-γ 抑制通过 AKT 途径减少了宫颈癌肿瘤的生长。这种效应代表了一个治疗机会,并为宫颈癌治疗提供了一个新的靶点。转染 Synuclein-γ siRNA 的宫颈癌细胞表现出显着抑制癌细胞增殖(P < 0.01)、细胞周期停滞在 G0/G1 期和细胞凋亡(P < 0.05)。此外,Synuclein-γ 的下调显着抑制了体内宫颈癌的生长。此外,在 Synuclein-γ siRNA 处理组中,AKT、c-Myc 和 Cyclin D1 的蛋白质水平远低于对照组。结论 Synuclein-γ 抑制通过 AKT 途径减少了宫颈癌肿瘤的生长。这种效应代表了一个治疗机会,并为宫颈癌治疗提供了一个新的靶点。转染 Synuclein-γ siRNA 的宫颈癌细胞表现出显着抑制癌细胞增殖(P < 0.01)、细胞周期停滞在 G0/G1 期和细胞凋亡(P < 0.05)。此外,Synuclein-γ 的下调显着抑制了体内宫颈癌的生长。此外,在 Synuclein-γ siRNA 处理组中,AKT、c-Myc 和 Cyclin D1 的蛋白质水平远低于对照组。结论 Synuclein-γ 抑制通过 AKT 途径减少了宫颈癌肿瘤的生长。这种效应代表了一个治疗机会,并为宫颈癌治疗提供了一个新的靶点。Synuclein-γ的下调显着抑制体内宫颈癌的生长。此外,在 Synuclein-γ siRNA 处理组中,AKT、c-Myc 和 Cyclin D1 的蛋白质水平远低于对照组。结论 Synuclein-γ 抑制通过 AKT 途径减少了宫颈癌肿瘤的生长。这种效应代表了一个治疗机会,并为宫颈癌治疗提供了一个新的靶点。Synuclein-γ的下调显着抑制体内宫颈癌的生长。此外,在 Synuclein-γ siRNA 处理组中,AKT、c-Myc 和 Cyclin D1 的蛋白质水平远低于对照组。结论 Synuclein-γ 抑制通过 AKT 途径减少了宫颈癌肿瘤的生长。这种效应代表了一个治疗机会,并为宫颈癌治疗提供了一个新的靶点。
更新日期:2019-11-01
down
wechat
bug